Scienture Holdings, Inc. - Common Stock SCNX 深 滬
等待開盤 12-19 09:30:00 美东时间
0.4984
-0.002
-0.32%
華盛通- 最 高0.5449
- 今 開0.5105
- 成交量 71.49万股
- 最 低 0.4984
- 昨 收 0.50
- 總市值 1228.96万
- 52周最高 6.56
- 市盈率 靜 --
- 換手率 2.90%
- 52周最低 0.461
- 委 比 95.65%
- 總股本 2465.82万
- 歷史最高 164.50
- 量 比 0.62
- 振 幅 9.30%
- 歷史最低 -5.81
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Scienture Stock Gaining Today?
Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.
12-10 22:53
SCIENTURE HOLDINGS Collaborates With BlinkRx For Expanded Patient Access To Arbli.
U.S. Losartan market totals $245M annually with 71M prescriptions U.S. Losartan market totals $245M annually with 71M prescriptions
12-10 21:07
Scienture Holdings Q3 EPS $(0.19) Up From $(1.34) YoY, Sales $590.050K Up From $64.861K YoY
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.19) per share. This is a 85.82 percent increase over losses of $(1.34) per share from the same period last year. The company reported $590.050 thousand
11-13 21:21
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
Scienture's Q3 revenue surged on Arbli sales, debt dropped, and cash rose to $8 million ahead of its planned Rezenopy launch in early 2026.
11-13 20:50
Scienture Holdings, Inc. shares are trading higher after the company announced that Arbli (losartan potassium) oral suspension was added to key national payor formularies, expanding commercial and Medicare coverage.
Scienture Holdings, Inc. shares are trading higher after the company announced ...
11-04 20:55
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Shares of Intel Corporation (NASDAQ:INTC) rose sharply in pre-market trading af...
10-24 17:25
Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?
Shares of Scienture Holdings, Inc. (NASDAQ: SCNX) are rising Thursday after the company announced the start of commercial sales for Arbli.
10-24 01:14
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
Scienture Holdings launched Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium, to address unmet market needs. The U.S. losartan market totals $256 million annually with 71 million prescriptions, presenting a significant opportunity. Arbli™ offers a safe, consistent, and convenient alternative to solid dosage forms, particularly for patients requiring liquid formulations. Scientific secured PBM-GPO agreements for ex...
10-23 12:05
Scienture Holdings Faces Nasdaq Non-Compliance Notice
Scienture Holdings ( ($SCNX) ) has shared an announcement. On October 14, 2025,...
10-18 05:30
SCIENTURE HOLDINGS Says Arbli Oral Suspension, 10mg/mL, Is Commercially Available Through Full-Line Wholesalers Nationwide
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tabletsU.S. losartan market totals $256M annually with 71M prescriptions, creating a significant
10-16 21:04
